medigraphic.com
ISSN 0188-2198 (Impreso)

2002, Número 1

Siguiente >>

Rev Mex Cardiol 2002; 13 (1)


Consenso Mexicano sobre el Tratamiento Integral del Síndrome Metabólico

Idioma: Español
Referencias bibliográficas: 88
Paginas: 4-30
Archivo PDF: 442.41 Kb.


FRAGMENTO

El grupo de estudio del síndrome metabólico, en cumplimiento a su compromiso de mantener actualizados los conceptos vertidos en el Primer Consenso de Resistencia a la Insulina y Síndrome Metabólico, llevó a cabo una serie de reuniones multidisciplinarias para llegar a una opinión uniforme, actualizada y consensada en relación al tratamiento del síndrome metabólico.
Las recomendaciones contenidas en este Consenso permitirá al equipo de salud identificar, prevenir, controlar y tratar los diversos componentes del síndrome metabólico de una manera integral. Los componentes del síndrome metabólico incluyen entre otros factores de riesgo cardiovascular a la diabetes mellitus tipo 2, la hipertensión arterial, la dislipidemia y la obesidad. La resistencia a la insulina suele ser el tronco común entre estas entidades que habitualmente se encuentran asociadas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kannel WB, Mcgee DL. Diabetes and Cardiovascular disease. The Framinghan Study. J AM Med Assoc 1997: 241: 2035-2038.

  2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 1595-1607.

  3. Albert KG, Zimmet PZ. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998; 15: 539-553.

  4. Isomaa B et al. Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. Diab Care 2001 24: 638-689.

  5. González C, Stern TA, Haffner S et al. The Insulin Resistance Syndrome in Mexico. Prevalence and clinical characteristics: A Population Based Study. Arch Med Res 1995; 26 (suppl): 59-515.

  6. Rantala AO, Kauma H, Lilja M et al. Prevalence of Metabolic Sindrome in drug-treated Hypertensive Patients and Control Subjects. J Intern Med 1999; 245(2): 163-174.

  7. Wannamethee SG, Shaper AG, Durrington PN et al. Hypertension, Serum-insulin, Obesity and Metabolic Syndrome. J Hum Hypertens 1998; 12(11): 735-741.

  8. Vanhala MJ, Kumpusato GA, Tkajarvitk P et al. Metabolic Syndrome in a Middle–Aged Finnish Population. J Cardiovasc Risk 1997; 4(4): 291-295.

  9. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and Mortality a Population–Based Study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 1998; 148(10): 958-966.

  10. ADA. Annual Review of Diabetes 2001.

  11. Derk Le Roith, Yehiel Zick. Recent Advances in our Understandind of Insulin Action and Insulin Resistance Diabetes Care 2001; 24(3): 59-70.

  12. DeFronzo RA. Insulin Resistence and Hyperinsulinemia: The Link Between NIDDM, Hypertension and Dyslipidemia. In: Schwartz CJ, Bon Gd (eds). New Horizons in Diabetes Mellitus and Cardiovascular Disease. London, UK; Current Science. 1995.

  13. Khan CR. The Insulin Receptor, Insulin Action and the Mechanism of Insulin Resistance in Diabetes and Atheroesclerosis: In: Schuartx CJ, Bom GV (eds). New Horizons in Diabetes Mellitus and Cardiovascular Disease. London, UK; Current Science. 1995.

  14. Bjorntorp P. Body Fat Distribution, Insulin Resistance, and Metabolic Diseases. Nutrition 1997; 13: 795-803.

  15. Despres JP, Larmarcha B, Meuriege MSP et al. Hyperinsulinemia as an Independent Risk Factor for Ischemic Heart Disease. N Engl J Med 1996; 334: 952-957

  16. Zimmet P, O’Dea K. Thrifty Genotype. Causes of Diabetes. Genetics and Enviromental Factors. De. DG Laslie. Wiley & Sons. Chichester 1993: 269-290

  17. American Diabetes Association. Consensus Development Conference on Insulin Resistance. Diabetes Care 1998; 21: 310-314.

  18. Grupo de Estudio del Síndrome Metabólico. Consenso Mexicano de Resistencia a la Insulina y Síndrome Metabólico. Rev Mex Cardiol 1999; 10(1): 3-18.

  19. Aresh J. Anwan, Authory HB, Sudhesh Kumar. The Metabolic Syndrome and Vascular Disease. Diabetes and Cardiovascular Disease. Edit. MICHEL T. Johnsture, MD, CM; FCRCP: Human Press 1ª. Edición 2001; 3-22.

  20. WHO Consultation on Obesity. Preventing and Managing the Global Epidemic. Geneva: World Health Organization 1997; 1-276.

  21. Lean Me. Waist Circumference as a Measure for Indicating need for Weight Management. BMJ 1995; 311: 158-161.

  22. Lean Me. Impairment of Health and Quality of Life in People with Large waist Circumference. Lancet 1998; 351: 853-856.

  23. Han TS. Waist Circumference Action Levels in the Identification of Cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311: 1401-1405.

  24. Jean-Pierre Despres. Treatment of Obesity: Need to fows on high risk abdominally obese patients. BMJ 2001; 322: 716-720.

  25. Isabelle Lemieux. Hipertriglycerinemic Waist. A marker of the atherogenic metabolic triad. Circulation 2000; 102: 179-184.

  26. White K, Gracy M. Schumacher L. Spargo R, Kretchmer N. Hyperinsulinemia and impaired glucose tolerance in young Australian Aborigens. Lancet 1990; 2: 735.

  27. Zimmet P, Dowse G, Benner P. Hyperinsulinemia is a predictor of non-insulin dependent diabetes mellitus. Diabetes Metab 1991; 17: 101-108.

  28. Serman SE et al. Comparison of past versus recent physical activity in the prevention of premature death and coronary artery disease. Am Heart J 1999; 138(5): 900-7.

  29. Yudkin JS, Albert, McLarty DG, Swai H. Impaired glucose tolerance. Is it a Risk Factor For diabetes or a diagnostic Ragbag? BMJ 1990; 301: 397-401.

  30. Eriksson KF, Lindgarde F. Prevention of non-insulin-dependent diabetes mellitus by diet and phisical exercise: the 6 year Malmo feasibility study. Diabetologia 1991; 34: 891-8.

  31. Pan X, Li G, Hu Y et al. Effects of diet and exercise in preventin NIDDM in people with impaired glucose tolerance: the DA Qing IGT and diabetes study. Diabetes Care 1997; 20: 537-44.

  32. Tuomilehto J, Lidstrom J, Erikksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.

  33. Sartor G, Scherster B, Carlstron S, Melander A, Norden A, Persson G. Ten Tears Follow up of subjects with Impaired Glucose Tolerance Prevention of Diabetes by Tolbutamide and Diet regulation. Diabetes 1980; 29: 41-49.

  34. Karunakaran S, Hammersley MS, Morris RJ, Turner Rc, Holman RR. The fasting Hyperglycemia Study: III. Randomized controlled trial of sulfonilurea therapy in subjects with increased but not diabetic plasma glucose. Metabolism 1997; 46 (suppl 1): 56-60.

  35. Chiasson JL, Nathan JM, Josse Rg et al. The efect of Acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190.

  36. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP–NIDDM Trial. Study to prevent type 2 diabetes. Diabetes Care 1998; 21: 1720-1725.

  37. Nagi DK, Yudkin JS. Effects of Metformin on insulin resistance, Risk Factors for Cardiovascular Disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-629.

  38. Li CL, Pan CY, Lu JM et al. Effect of metformin on patients with impaired glucose tolerance. Diab Med 1999; 16: 477-81.

  39. Taylor T. The effect of Orlistat on glucose tolerance in obese non diabetic individuals. Diabetologia 1997; 40 (suppl 1): A 197.

  40. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235-242.

  41. Bray GA, Blackbum GL, Ferguson JM et al. Sibutramina produces dose-related weight loss. Obes Res 1999; 7: 189-198.

  42. Stock MJ. Sibutramine: a review of therfarmacology of a novel anti-obesity agent. Int Obesity 1997; 21 (suppl 1): S25-29.

  43. Hanontil C, Thomas F, Jones SP et al. Efficacy and tolerability of sibutramine in obese patients: a dose raining study. In J Obesity 1998; 22: 32-38.

  44. Clifford JB. The Diabetes Prevention Program: Headline Results. Br J Diabetes Vasc Dis 2001; 1: 62-64.

  45. Stratton MI, Adler AL, Neil Ha et al. Association of Glicaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36); Prospective observational study. Br Med 2000; 21: 405-12.

  46. Ohkubo Y, Kishikama H, Araki E et al. Intensive insulin therapy prevents the progresion of diabetic microvascular complications in japanese patients with non insulin dependent diabetes mellitus: a randomized prospective 6 years study. Diabetes Res Clin Pract 1995; 28: 103-117.

  47. Campbell IW. Need for intensive early glycaemia control in patients with type 2 diabetes. Brit J Cardiol 2000; 7: 625-31.

  48. UKPDS Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352 (9131): 854-865.

  49. Bakris Gl, Williams M, Dworkin L et al. Preserving Renal Function in Adults with Hypertension and diabetes: a consensus report. Am J Kid Dis 2000; 36: 646-61.

  50. UK Prospective Diabetes Study Group. Tight blood Pressure control and Risk of Macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-13.

  51. HOT Study Group: Effects of intensive Blood-presure lower-ing and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.

  52. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.

  53. Ames RP, Hill P. Elevation of serum lipids during diuretic treatment of hypertension. Am J Med 1976; 61: 748-752.

  54. Samuelsson O, Hedner T, Berglund G et al. Diabetes mellitus in treated hypertension: incidence, predictive tiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens 1999; 8: 257-263.

  55. Savage PJ, Pressel SL, Curb JD et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolates systolic hypertension: the Systolic Hypertension in the Elderly Program. Arch Intern Med 1998; 158: 741-751.

  56. Systolic Hypertension in the Elderly Program Cooperative Research Group: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-1892.

  57. Mediratta MD, Fozailoff MD, Frishman MD. Insulin Resistance in Systemic Hypertension: Pharmacotherapeutic Implications. J Clin Pharmacol 1995; 35: 943-956.

  58. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 39. BMJ 1998; 317: 713-720.

  59. Hamich C, Ciaven E, Sheridan B. Effect of the alpha blocker Doxazosin on insulin action in essential hypertension. J Am Diabetes 2000; 149 (S1): S369.

  60. Schneider M, Lerch M, Papiri M, Buchel P et al. Metabolic neutrality of combined verapamil-trandolaprim treatment in contrast beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1996; 14: 669-677.

  61. Valesi P, Uzzan B, Attali JR, Perret G. Effects of nifedipine and nitrendipine on insulin secretion in obese patients. J Cardiovasc Pharmacol 1991; 18 (S1): S91-S93.

  62. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine Gits Study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366-372.

  63. Alain S. Efectos Diferentes de nifedipino coamilozida sobre la progresión de las alteraciones iniciales de la pared carotídea. Circulation 2001; 103: 2949-2954.

  64. The Heart outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzime inhibitor, ramipril on cardiovascular events in high risk patients. N England J Med 2000; 342: 145-153.

  65. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular out-comes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.

  66. Hansson L, Lindholm LH. Effects of angiotensin-converting-enzime inhition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The captopril prevention proyect (CAPPP) randomized trial. Lancet 1999; 535: 611-616.

  67. Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP et al. The Losartan renal protection study-rationale, study design and baseline characteristics of RENAAL. JRAAS 2000; 1: 328-335.

  68. Hans-Henrik Parving. Hypertension and Diabetes: The Scope of the problem. Blood Pressure 2001;10 (supp 2): 25-35.

  69. Bernard W. Achieving Blood Pressure. Targets in the management of hypertension. Blood Pressure 2001; 10 (suppl 2): 6-12.

  70. Weber M. Emerging Treatments for hypertension: Potential role of vasopeptidase inhibition. Am J Hypertens 1999; 12: 139S-147S.

  71. Burnett JC Jr. Vasopeptidase inhibition, a new concept in blod pressure management. J Hypertension 1999; 17(S1): S37-S43.

  72. González A, Alexánderson G, Camacho J, Quiñonez S y cols. La teoría metabólica en la génesis de la hipertensión arterial. Agentes antihipertensivos e implicaciones farmacoterapéuticas. Rev Mex Cardiol 2000; 11(4): 314- 322

  73. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.

  74. American Diabetes Association: Management of Dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 2000; 23 (suppl 1): S57-S60.

  75. Third Report of National Cholesterol Education Program. (NCEP) Expert Panel on Detection and Evaluation on Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486-2497.

  76. British Cardiac Society, British Hyperlipidemia Association, British Hypertension Society endorsed by British Diabetic Association. Joint British recommendations on prevention of coronary Heart disease in Clinical Practice. Heart 1998; 80 (suppl 2): 51-529.

  77. Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.

  78. Air Force-Texas Coronary Atherosclerosis Prevention Study Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex CAPS. JAMA 1998; 279: 1615-1622.

  79. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410-418.

  80. Pyorala K. Ensayo Escandinavo de sobrevida con Simvastatina. Diabetes Care 1997; 20: 614-20.

  81. Diabetes Atherosclerosis Intervention Study investigators. Effect of Fenofibrato on progression of coronary disease in type 2 diabetes. The Diabetes Atherosclerosis Intervention Study (DAIS). Lancet 2001; 357: 905-10.

  82. Aronne LJ. Modern Medical Management of obesity: The role of Pharmaceutical Intervention. J Am Diet Assoc 1998; 98 (suppl 2): S23-6.

  83. Rossanen A. Pharmacological intervention: the antiobesity approach. Gur Clin Invest 1998; 28 Suppl 2: 27-30. University Kelsinki, Finland.

  84. Bray GA. Medicinal strategies in the treatment of obesity. Nature 2000; 404 (6778): 672-7 Pennington Biomedical, Louisiana.

  85. Berke EM, Morden Nf. Medical management of obesity. Am Fam Physician 2000; 62(2): 419-26. University of Massachusetts.

  86. John B Buse. Progression use of medical therapies in type 2 diabetes. Diabetes Spectrum 2000; 13 (4): 111-122.

  87. Rissanen A. Pharmacological intervention. Eur J Clin Invest 1998; 28 Suppl 2: 27-30.

  88. González-Ortiz M. Comparison of homeostasis model analysis with insulin tolerance test in the assessment of insulin resistance in healthy young people. Diab Nutr Metab 1998; 11: 36-139.




2020     |     www.medigraphic.com